Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Multicenter, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Moderate to Severe Plaque Psoriasis

Next Previous
X
Search
Trial Profile

A Phase 2b, Randomized, Multicenter, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Moderate to Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zasocitinib (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Nimbus Therapeutics

    • Most Recent Events

    • 12 Mar 2024 Results investigating associations between TAK-279 treatment, psoriasis/TYK2 biomarkers and clinical/histologic response, presented at the American Academy of Dermatology annual Meeting 2024
    • 20 Mar 2023 Results published in the Nimbus Therapeutics Media Release.
    • 18 Mar 2023 According to Takeda media release, the company will be hosting a virtual meeting for investors and analysts to discuss the study data.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top